RECENTLY ADDED

  • Treatment of Opioid Use Disorder: Waiver Qualifying - Johns Hopkins Nursing - Saturday, September 22, 2018

    Contains 3 Component(s), Medical Credits Offered

    The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers treating opioid use disorder by using interactive, case-based learning to teach evidence-based practices. This course is SAMHSA-supported and meets the requirements needed to obtain the waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    image

    Saturday, September 22, 2018 | 8:00 am - 5:30 pm

    Johns Hopkins School of Nursing
    Pinkard Building, Room 217
    525 N. Wolfe Street
    Baltimore, MD 21205

    Cost: FREE

    Hosted by: 
    Johns Hopkins School of Nursing


    Welcome to the ASAM Treatment of Opioid Use Disorder Course. Please LOG IN or Create a New Account to register for the course. If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password.

    This 8-hour live course covers all treatments and medications for opioid use disorder, and is designed for licensed physicians, nurse practitioners, and physicians assistants who plan to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.

    Once you have completed the live course, return here to claim CME for the course. If you have any questions, please contact education@ASAM.org.


    Overview of Legislation

    Physicians

    The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office ‐ based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

    Nurse Practitioners & Physician Assistants

    On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

    To qualify, NPs and PAs must: 

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
    • Complete not less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD  
    • If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

    ASAM, AAPA and AANP have formed a collaborative to provide the 24-hour waiver training for physician assistants and nurse practitioners. The three organizations are authorized by statute to provide this training. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat Opioid Use Disorder before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs/PAs from prescribing these medications even if Federal law allows it. Click here to learn more about applying for the waiver.

    This training is divided into two parts of 8 hours and 16 hours. This 8 hour course will satisfy Part 1 and Part 2 can be completed online for free.

    For NPs (CE Credit through AANP): Click Here
     
    For PAs (AAPA Category 1 CME Credit): Click Here


    Click here to view additional resources.

    Upon completion of the live course, you will be able to claim CME Credit through the ASAM e-Learning Center after completing the evaluation module. 

    CME Information and Disclosure Listing

    Date of Release: July 2015
    Approved Through: December 2019

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

    The American Society of Addiction Medicine designates this live activity for a maximum of 8 AMA PRA Category 1 Credits

    In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Dan Alford, MD, MPH, DFASAM, Chair

    None

    Paula J. Lum, MD, MPH, FASAM, Vice Chair

    None

    Edwin Salsitz, MD, DFASAM, Curriculum Director

    None

    Soraya Azari, MD

    None 

    Jill Mattingly, DHSc, MMSc, PA-C

    None

    Debra Newman, PA-C, MPAS, MPH

    None

    Mary McMasters, MD, DFASAMNone

    Yngvild K. Olsen, MD, MPH, DFASAM

    None
    Shawn Ryan, MD, MBA, FASAMAdapt Pharma OrexoConsulting Fee HonorariumContent Expert Speaker
    Kristin Smith, DNP, FNP-C, AAHIVSNone
    Tricia E. Wright, MD, MS, FACOG, FASAMNone

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine Friedman, MD, FAPA, DFASAM, Chair

    None

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Zwaantje Hamming, FNP-C, CARN-APNone

    Herbert L. Malinoff, MD, FACP, DFASAM

    None

    Noel Ilogu, MD, MRCP, DFASAM

    None

    Edwin A. Salsitz, MD, DFASAM

    None

    ASAM Staff and Consultants

    Arlene C. Deverman, MA, CAE, CFRENone

    Marcia Jackson, PhD

    None
    Sandy MetcalfeNone

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair

    Pfizer  Johnson & Johnson Pfizer CanadaGrant funding Consulting Fees Consulting FeesPrincipal  Investigator Consulting Consulting
    Daniel P. Alford, MD, MPH, DFASAMNone
    Michael Fingerhood, MD, FACP, FASAMNone
    Catherine R. Friedman, MD, FAPA, DFASAMNone
    Adam J. Gordon, MD, MPH, FACP, DFASAMNone
    Miriam S. Komaromy, MD, FACP, DFASAMNone
    Edwin A. Salsitz, MD, DFASAMNone
    Mark P. Schwartz, MD, DFASAMNone
    Mark A. Weiner, MD, FASAMNone
    ASAM Staff and Consultants
    Penny S. Mills, MBANone
    Arlene C. Deverman, MA, CAE, CFRENone
    Marcia Jackson, PhDNone
    Dawn C. HowellNone
    Molly S. MazukNone
    Alexandra (Alli) UngerNone
    Jennifer L. ButchartNone
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 8 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    At the conclusion of this activity, learners should be able to:

    1. Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
    2. Identify and assess patients who are appropriate for treatment with medications
    3. Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
    4. Discuss the psychiatric and medical co-morbidities associated with opioid addiction

    Licensed physicians, nurse practitioners, and physician assistants who wish to treat patients with opioid use disorder and to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.



    1. Fill out the survey by clicking the blue “Fill out Survey” button in the box titled “The ASAM Treatment of Opioid Use Disorder Course Live Portion Evaluation” at the end of the training. 

      1. Pro tip: Be sure to scroll down on all Likert Scale questions. There are answers that expand past the size of the survey window

    2. Submit the evaluation. (The next box should activate and the evaluation box should turn green with a white check mark)

    3. Click the button “Claim Medical Credits” in the box titled “CME Certificate”

    4. Choose the type of credit (Physician or Non-physician) and click submit

    5. Click the button “View/Print Certificate” to save or print your certificate
      1. Pro tip: If you ever lose your certificate, you can come back to the e-Learning Center and view it on your Transcript (found on Dashboard)


    Click here for more information on applying for a waiver to prescribe buprenorphine.

    Apply

    NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.

    NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.gov or fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.

    SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number. 

    Qualify

    To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:

    • Be licensed under state law to prescribe schedule III, IV, or V medications for pain
    • Complete no less than 24 hours of appropriate education through a qualified provider
    • Through other training or experience, demonstrate the ability to treat and manage OUD
    • If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

    Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.

  • ASAM Review Course Spotlight Webinar Series 2018 (6 CME)

    Contains 24 Component(s), Medical Credits Offered

    Register now to earn a maximum of 6 CME while attending this six-webinar series, which will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine 2018. Topics include; psychiatric co-morbidities, cannabis, tobacco, prevention and public health, pharmacology and toxicology, and pain and addiction.

    image

    REVIEW COURSE ATTENDEES RECEIVE 25% OFF - Use the promo code located in your syllabus when checking out to take advantage of this special deal!

    Looking to stay engaged and expand your ASAM Review Course experience? This six-webinar series will offer an additional, in-depth look at some of the most popular sessions from the ASAM Review Course in Addiction Medicine. 

    Each webinar will be an hour long, with 30-45 minutes of lecture on the topic of the week and the rest saved for audience questions. Questions have been collected in advance from participants of the 2018 Review Course and all attendees will have the opportunity to submit questions during the live webinar!

    All webinars will be recorded and available to watch for registrants unable to attend live. 

    DateTime (Eastern)
    Topic
    Tuesday, August 2812:00 pm – 1:00 pmCannabis
    Carla Marienfeld, MD
    Thursday, August 3012:00 pm – 1:00 pmTobacco
    Abigail Herron, DO, FAPA, DFASAM
    Wednesday, September 512:00 pm – 1:00 pmPrevention and Public Health
    Sharon Stancliff, MD, FASAM
    Friday, September 712:00 pm – 1:00 pmPharmacology and Toxicology
    Timothy Wiegand, MD, FACMT, FAACT
    Monday, September 1012:00 pm – 1:00 pmPain and Addiction
    Edwin Salsitz, MD, DFASAM
    Wednesday, September 1212:00 pm – 1:00 pmPsychiatric Co-Morbiditie
    Richard Ries, MD, DFASAM


    Additional Resources

    Additional Board Exam Preparation resources and tools are also available.


    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    Richard K. Ries

    MD, DFASAM

    Richard K. Ries, MD, is Professor of Psychiatry, and Director of the Addictions Division in the Department of Psychiatry and Behavioral Sciences at the University of Washington School of Medicine in Seattle, Washington and Director of the Addiction Treatment services at Harborview Medical Center in downtown Seattle. Dr. Ries received his undergraduate degree from Stanford, medical degree from Northwestern Medical School and completed his psychiatric residency at the University of Washington, Seattle, where he was Chief Resident. 

    Dr. Ries is board-certified in Psychiatry by the American Board of Psychiatry and Neurology with Added Qualifications in Addiction Psychiatry, and the American Board of Addiction Medicine.  A Distinguished Fellow of the American Psychiatric Association and a Fellow of the American Society of Addiction Medicine, he is on the editorial board and a reviewer for several scientific journals and holds a number of research grants from the National Institute of Health. 

    He has published numerous articles and abstracts on topics related to treatment of persons with severe mental illness, with special emphasis on those with co-existing problems with alcohol or drugs, and was the chair and co-chair of TIPS 9 and 42 on Treatment of Persons with Co-occurring  Addiction and Mental Disorders published by the national Center of Substance Abuse Treatment (CSAT).  He is senior editor of  the key reference text:  Principles of Addiction Medicine (edition V, 2014), published by the American Society of Addiction Medicine, and a noted expert in the  field of Addictions.

    Carla Marienfeld

    MD

    Carla Marienfeld, MD, is an addiction psychiatrist and an Associate Clinical Professor of Psychiatry at University of California San Diego. Clinically, she focuses on the treatment of patients with substance use disorders and co-morbid psychiatric conditions. She previously worked at a large outpatient addiction treatment program serving over 5000 patients. Her academic interests focus on implementation research and large-data health outcomes for patients with substance use disorders. She attended Baylor College of Medicine in Houston, TX, where she completed the International Health Track, served nationally on the Board of Trustees of the American Medical Student Association (AMSA), and earned Alpha Omega Alpha (AOA) Medical Honors Society and Honors distinction. During psychiatry residency at Yale, she served as chief resident, a National Institute of Drug Abuse R25 Research Fellow, and as the resident representative to the Accreditation Council for Graduate Medical Education (ACGME), while also earning several awards and fellowships. She completed a fellowship in Addiction Psychiatry at Yale. During residency and her early faculty years, she founded and led the Yale Global Mental Health Program. She served as the site training director for the Yale New Haven Hospital Addiction Psychiatry Fellowship and supervised and taught medical students for psychiatry, residents for global mental health, and fellows for addiction psychiatry. She has come to UCSD to help in the development and implementation of a new Addiction Recovery and Treatment Program and a new Addiction Psychiatry Fellowship.

    Abigail J. Herron

    DO, DFASAM, FAPA

    Abigail J. Herron, DO, is the Director of Psychiatry and the Director of the Fellowship in Addiction Medicine at the Institute for Family Health.  She is board certified in adult psychiatry, addiction psychiatry and addiction medicine, and is an Assistant Professor of Psychiatry at the Icahn School of Medicine at Mt. Sinai.  

    Dr. Herron is a fellow of the American Psychiatric Association and a Distinguished Fellow of the American Society of Addiction Medicine.  She graduated from Wesleyan University and the University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine.  Dr. Herron completed her psychiatry residency at St. Luke's and Roosevelt Hospitals, where she was also chief resident, and a clinical research fellowship in addiction psychiatry at Columbia University and the New York State Psychiatric Institute.  

    Her academic interests include integrated care, women’s health, and medical education.  She is the co-editor of the Addiction Casebook, and the editor-in-chief of ASAM’s Essentials of Addiction Medicine.  Dr. Herron is also in private practice in New York City. 

    Sharon Stancliff

    MD, FAAFP

    Sharon Stancliff, M.D. is the Medical Director of the Harm Reduction Coalition She oversees SKOOP, which provides overdose prevention services both directly in New York City and through education and capacity building nationally and internationally. Dr. Stancliff also consults on drug related problems for the AIDS Institute, New York State Department of Health and for several international organizations. 

    Dr. Stancliff graduated from the School of Medicine at University of California at Davis, did her Family Practice residency at the University of Arizona and completed the AIDS Institute-sponsored Nicolas Rango HIV Clinical Scholars Program at Beth Israel Medical Center in New York City. She is board certified in Family Medicine, a Fellow of the American Academy of Family Practice, and certified by the American Board of Addiction Medicine. She serves as secretary for the New York Society of Addiction Medicine.

    Timothy J. Wiegand

    MD, FACMT, FAACT, FASAM

    Tim Wiegand MD, DABAM, FACMT, FAACT was trained in internal medicine and completed fellowship training in Medical Toxicology at the University of California, San Francisco in 2006. He was the Medical Director of the Rochester Poison Center until 2010. Dr. Wiegand has been successful in developing a full time, bedside, medical toxicology consultation service and is very active in the practice of Addiction Medicine, having successfully completed his board certification recently. 

    In addition to his primary appointment as Associate Professor of Emergency Medicine at the University of Rochester School of Medicine & Dentistry in Rochester, NY, Dr. Wiegand serves as Medical Director for Huther Doyle Chemical Dependency Treatment Program in Rochester, NY and as a detoxification specialist for Syracuse Behavioral Health in Rochester, NY. 

    Dr. Wiegand serves on the New York Society of Addiction Medicine (NYSAM) Board of Directors as the Communication Committee Chair and he was recently elected to the American College of Medical Toxicology Board of Directors to begin a 3 year term in October, 2015. He currently serves as the chair of the Addiction Medicine Section for the American College of Medical Toxicology and he recently organized a very successful Addiction Medicine Academy for ACMT prior to their main Annual Scientific Meeting in Clearwater, Florida in March, 2015. Dr. Wiegand has presented for the ASAM Review Course on Pharmacology & Toxicology, MRO and drug testing principles at previous Review Course conferences.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 6 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 6 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO, Chair

    None

     

     

    Catherine Friedman, MD

    Vice Chair

    None

     

      

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    John C. Tanner, DO, DABAM, DFASAM, CCFC, MRO

    Indivior

    BDSI

    Honorarium

    Honorarium

    Speaker

    Consultant/Speaker

      The ASAM Review Course Program Planning Committee Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

     

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, INC

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

     

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA Rollover Account

    Stock Options

    (Spouse)

     

    Bonds in IRA

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

    The ASAM Review Course Faculty Member Disclosure Listing

    Name

    Commercial Interest

    What was received?

    For what role?

    Petros Levounis, MD, MD, DFASAM

    None

     

     

    Abigail Herron, DO, DFASAM, FAPA

    None

     

     

    Timothy K. Brennan, MD, MPH, FASAM

    None

     

     

    Jeffrey DeVido, MD, MTS

    Philip Morris

     

     

    Altria

    Ownership Interest

     

    Ownership Interest

    Equity Shareholder

     

    Equity Shareholder

    Paul H. Earley, MD, DFASAM

    Alkermes

     

    Georgia PHP, INC

     

    Earley Counsultancy, LLC

     

    DynamiCare Health, INC

    Honoraria

     

    Salary

     

     

    Salary

     

     

     

    Salary

    Speaker

     

    Medical Director

     

     

    Principal

     

     

     

    Speaker

    James W. Finch, MD, DFASAM

    Orexo Pharmaceuticals

     

    Indivior Pharmaceuticals

    Honoraria

     

     

    Honoraria

    Speaker

     

     

    Speaker

    Marc Fishman, MD, DFASAM

    Alkermes

     

     

    US WorldMeds

     

     

     

     

    MediaRez

    Salary

     

     

    Salary

     

     

     

     

    Research Funding

    Consultant; Advisory Board

     

    Consultant; Advisory Board; Principal Research Investigator

     

    Principal Research Investigator

    David Galbis-Reig, MD, DFASAM

    Abbot Pharmaceuticals

     

    AbbVie

     

     

    Cortex Pharmaceuticals

    GW Pharmaceuticals

     

    Hospira

     

     

    Pfizer, Inc

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Ownership Interest

     

    Ownership Interest

     

    Ownership Interest

    Stock Options

     

     

    Stock Options

    (spouse)

    Stock Owned through IRA Rollover Account

    Stock Owned through IRA

     

    Rollover Account

    Stock Options

    (Spouse)

    Bonds in IRA

    Leslie Hayes, MD

    None

     

     

    Carla Marienfield, MD

    None

     

     

    Ricardo Restrepo, MD, MPH

    None

     

     

    Richard Ries, MD, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Sharon Stancliff, MD

    None

     

     

    Timothy J. Wiegand, MD, FACMT, FAACT, FASAM

    None

     

     

    Erin Zerbo, MD

    None

     

     

  • The ASAM Review Course in Addiction Medicine 2018 (20.5 CME)

    Contains 24 Product(s)

    Earn up to 20.5 CME while preparing for the ABPM Addiction Medicine Exam using this on-demand package of courses, containing the conference recordings, resources, practice questions, and slides from The ASAM Review Course in Addiction Medicine, 2018. The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    image

    Overview

    The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.

    The course offers two and a half days of sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. Over 600 professionals attend this popular course each time it is offered. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.

    Learning Objectives

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse

    Additional Resources

    Additional Board Exam Preparation resources and tools are also available.


    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The ASAM CME Committee and Reviewers Disclosure Listing

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None

    ACCME Accreditation Statement:

    The American Society of Addiction Medicine is accredited by the Accreditation Council for
    Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement:

    The American Society of Addiction Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    American Academy of Family Physicians: 

    This Live activity, The 2018 ASAM Review Course in Addiction Medicine & Pre-Courses, with a beginning date of 07/25/2018, has been reviewed and is acceptable for up to 27.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABAM Transitional Maintenance of Certification Program (Tmoc)

    This course has been approved by The American Board of Addiction Medicine (ABAM).  Physicians enrolled in the Transitional Maintenance of Certification (Tmoc) Program can apply a maximum of 20.5 AMA PRA Category 1 Credits

    American Psychological Association (APA)

    The American Society of Addiction Medicine (ASAM) Continuing Medical Education (CME) has been approved for renewal of certification by the APA College of Professional Psychology. ASAM CME credits may be applied toward the APA’s “Certificate of Proficiency in the Treatment of Alcohol and Other Psychoactive Substance Use Disorders.”

    Continuing Education Credits (CEUs)

    Non-physician participants will receive a certificate of attendance upon completion of the activity and an online evaluation confirming their participation. Participants should submit his/her certificate of attendance to their professional organization/institute.

    CME Committee Members

    • Catherine Friedman, MD, FASAM, Chair
    • R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
    • Adam J. Gordon, MD, MPH, FACP, DFASAM
    • Zwaantje Hamming, FNP-C, CARN-AP
    • Noel Ilogu, MD, MRCP, FASAM
    • Herbert L. Malinoff, MD, FACP, DFASAM
    • Edwin A. Salsitz, MD, DFASAM

    Staff - Sandy Metcalfe; Arlene Deverman, MA, CAE, CFRE; Marcia Jackson, PhD

    CME Committee, Program Planning Committee and Faculty Disclosure Information

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These polices include resolving all conflicts of interest between the CME Committee, planning committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    Upon completion, participants should be able to:

    1. Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
    2. Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
    3. Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
    4. Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
    5. Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.

    The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:

    • Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
    • Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
    • Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients 
  • Pain Management and Opioids: Balancing Risks and Benefits (2.5 CME)

    Contains 5 Component(s), Medical Credits Offered Recorded On: 07/25/2018

    Earn a maximum of 2.5 AMA PRA Category 1™ Credit(s) while reviewing prescribing habits and examine the difference between extended release/long acting medications to help ensure patient safety and effective pain management.

    image

    The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

    • From 2000 to 2015 more than half a million people died from drug overdoses.
    • 91 Americans die every day from an opioid overdose.

    The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

    Learners will be able to:

    1. Accurately assess patients with pain for consideration of an opioid trial
    2. Establish realistic goals for pain management and restoration of function
    3. Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
    4. Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
    5. Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
    6. Educate patients about safe storage and disposal of opioids
    7. Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

    Edwin A. Salsitz

    MD, DFASAM

    Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project. 

    Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids. 

    Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services.  Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.

    CME Information and Disclosure Listing

    The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.  

    The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

    In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.  

    ASAM CME Committee

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Catherine R. Friedman, MD, FAPA, DFASAM, Chair

    None

     

     

    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

     

    Zwaantje Hamming, FNP-C, CARN-AP

    None

     

     

    Noel Ilogu, MD, MRCP, DFASAM

    None

     

     

    Hebert L. Malinoff, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Sandy Metcalfe

    None

     

     

    Program Planning Committee

    Faculty

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Herbert Malinoff, MD, FACP, DFASAM

    None

     

     

    Yngvild Olsen, MD, MPH

    None

     

     

    Theodore Parran, MD, FACP

    None

     

     

    Edwin Salsitz, MD, DFASAM

    None

     

     

    R. Corey Waller, MD, MS, FACEP

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

      ASAM CME Committee Reviewers

    ASAM Medical Education Council

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Jacob Bobrowski, MD, FAAFP

    None

     

     

    Anthony H. Dekker, DO, DFASAM

    None

     

     

    Name

    Nature of Relevant Financial Relationship

    Commercial Interest

    What was received?

    For what role?

    Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair

    Pfizer

    Johnson & Johnson

    Pfizer Canada

    Grant funding

    Consulting Fees

    Consulting Fees

     Principal Investigator

    Consulting

    Consulting

    Daniel Alford, MD, MPH

    None

     

     

    Michael Fingerhood, MD, FACP, FASAM

    None

     

     

    Catherine R. Friedman, MD, FAPA, DFASAM

    None

     

     

    Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO

    None

     

      

    Miriam S. Komaromy, MD, FACP, DFASAM

    None

     

     

    Edwin A. Salsitz, MD, DFASAM

    None

     

     

    Mark P. Schwartz, MD, DFASAM

    None

     

     

    Mark A. Weiner, MD, FASAM

    None

     

     

    ASAM Staff and Consultants:

     

     

     

    Arlene C. Deverman, MA, CAE, CFRE

    None

     

     

    Marcia Jackson PhD

    None

     

     

    Jennifer L. Butchart

    None

     

     

    Penny S. Mills, MBA

    None

     

     

     

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 2.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 2.5 AMA PRA Category 1 Credit(s)™ for completing this course.

    Acknowledgement

    Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

    RPC Commercial Support Disclosure Statement

    This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

    This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

  • Board Exam Study Tool (BEST) - 2018 (12 CME)

    Contains 5 Component(s), Medical Credits Offered

    Earn a maximum of 12 CME while learning from the BEST. This study tool helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format.

    image

    The ASAM Board Examination Study Tool (BEST) helps prepare physicians for the ABPM certification/re-certification examination utilizing an interactive and engaging format. 

    This powerful study tool includes: 

    1. Bank of 600 self-assessment questions reviewed for accuracy by addiction medicine experts
    2. Content derived from the ABPM Exam Blueprint for effective study guidance
    3. Excerpts and highlights from ASAM’s Essentials of Addiction Medicine and Principles of Addiction Medicine
    4. Glossary of important terms and definitions
    5. Additional resources recommended by Review Course faculty and experts for each topic
    6. 12 CME Credits upon completion
    7. Fully searchable functionality and content
    8. Access to the BEST 24/7 online at ASAM's e-Learning Center

    Live attendees of the 2018 ASAM Review Course in Addiction Medicine in Dallas, TX receive the 2018 BEST complimentary with registration. 

    Additional Board Exam Preparation resources and tools are also available.

    Goals and Objectives

    Upon completion of this education activity, participant should be able to:

    • Differentiate between important terms and definitions in the field of Addiction Medicine.
    • Distill knowledge on key points from the text, the Principles of Addiction Medicine, 5th edition and course slides
    • Appraise addiction patient cases and respond accurately to questions about next steps and treatment options.
    • Employ knowledge gained in the educational sections of the BEST to respond accurately to self-assessment questions.

    Participants of the 2018 ASAM Review Course in Addiction Medicine and other physicians who are preparing for the ABPM Certification Exam in Addiction Medicine.

    First Name Commercial Interests Compensation Received For what Role?
    Timothy Brennan MD, MPH, FASAM None
    Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance
    Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs 
    James Finch MD, DFASAM None

    Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board
    David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests  Owner; Advisory board; PI; Consultant
    R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None
    Adam Gordon, MD, MPH None
    Leslie Hayes, MD None
    Abigail Herron DO, DFASAM None
    Petros Levounis MD, MA, FASAM None
    Carla Marienfeld MD None
    Ricardo Restrepo MD, MPH, FASAM None
    Richard Ries MD, DFASAM None
    Edwin Salsitz MD, DFASAM None
    Sharon Stancliff MD, FASAM None
    Timothy Wiegand MD, FACMT, FAACT None
    Erin Zerbo, MD None
    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 12 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 12 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 12 AMA PRA Category 1 Credit(s)™ for completing this course.